SG10201607595WA - Novel conjugates, preparation thereof, and therapeutic use thereof - Google Patents
Novel conjugates, preparation thereof, and therapeutic use thereofInfo
- Publication number
- SG10201607595WA SG10201607595WA SG10201607595WA SG10201607595WA SG10201607595WA SG 10201607595W A SG10201607595W A SG 10201607595WA SG 10201607595W A SG10201607595W A SG 10201607595WA SG 10201607595W A SG10201607595W A SG 10201607595WA SG 10201607595W A SG10201607595W A SG 10201607595WA
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- therapeutic use
- novel conjugates
- conjugates
- novel
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/08—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and more than one oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D245/06—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0903170A FR2947269B1 (en) | 2009-06-29 | 2009-06-29 | NEW ANTICANCER COMPOUNDS |
FR0905651A FR2947271B1 (en) | 2009-06-29 | 2009-11-25 | NEW ANTICANCER COMPOUNDS |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201607595WA true SG10201607595WA (en) | 2016-11-29 |
Family
ID=41611078
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011097193A SG177419A1 (en) | 2009-06-29 | 2010-05-20 | Novel conjugates, preparation thereof, and therapeutic use thereof |
SG10201607595WA SG10201607595WA (en) | 2009-06-29 | 2010-05-20 | Novel conjugates, preparation thereof, and therapeutic use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011097193A SG177419A1 (en) | 2009-06-29 | 2010-05-20 | Novel conjugates, preparation thereof, and therapeutic use thereof |
Country Status (30)
Country | Link |
---|---|
US (1) | US8952147B2 (en) |
EP (1) | EP2448929A1 (en) |
JP (1) | JP5746692B2 (en) |
KR (1) | KR101770584B1 (en) |
CN (1) | CN102482238B (en) |
AR (1) | AR078131A1 (en) |
BR (1) | BRPI1015131A2 (en) |
CA (1) | CA2766762C (en) |
CL (1) | CL2011003229A1 (en) |
CO (1) | CO6430462A2 (en) |
CR (1) | CR20110670A (en) |
DO (1) | DOP2011000376A (en) |
EA (1) | EA024627B1 (en) |
EC (1) | ECSP11011553A (en) |
FR (2) | FR2947269B1 (en) |
HN (1) | HN2011003414A (en) |
IL (1) | IL217208A (en) |
MA (1) | MA33465B1 (en) |
MX (1) | MX2011013764A (en) |
MY (1) | MY156684A (en) |
NI (1) | NI201100219A (en) |
NZ (1) | NZ597136A (en) |
PE (1) | PE20121031A1 (en) |
SG (2) | SG177419A1 (en) |
SV (1) | SV2011004086A (en) |
TN (1) | TN2011000636A1 (en) |
TW (1) | TW201110986A (en) |
UY (1) | UY32745A (en) |
WO (1) | WO2011001052A1 (en) |
ZA (1) | ZA201109537B (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL305084A (en) | 2005-08-24 | 2023-10-01 | Immunogen Inc | Process for preparing purified drug conjugates |
LT2437790T (en) | 2009-06-03 | 2019-06-10 | Immunogen, Inc. | Conjugation methods |
NZ597050A (en) | 2009-06-29 | 2014-02-28 | Incyte Corp | Pyrimidinones as pi3k inhibitors |
US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
AR084366A1 (en) | 2010-12-20 | 2013-05-08 | Incyte Corp | N- (1- (REPLACED PHENYL) ETIL) -9H-PURIN-6-AMINAS AS PI3K INHIBITORS |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
KR20220009505A (en) | 2011-03-29 | 2022-01-24 | 이뮤노젠 아이엔씨 | Preparation of maytansinoid antibody conjugates by a one-step process |
BR122019020716B1 (en) | 2011-09-02 | 2021-02-17 | Incyte Holdings Corporation | heterocyclylamines as pi3k inhibitors and pharmaceutical composition comprising them |
AR090548A1 (en) | 2012-04-02 | 2014-11-19 | Incyte Corp | BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS |
SG11201502429YA (en) | 2012-10-04 | 2015-04-29 | Immunogen Inc | Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates |
CN105593238B (en) | 2013-07-11 | 2020-09-08 | 诺华股份有限公司 | Lysine-specific chemoenzymatic protein modification using microbial transglutaminase |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
CR20170111A (en) * | 2014-09-03 | 2017-05-23 | Immunogen Inc | CYTOTOXIC BENZODIAZEPIN DERIVATIVES |
GB201416960D0 (en) | 2014-09-25 | 2014-11-12 | Antikor Biopharma Ltd | Biological materials and uses thereof |
MD3262046T2 (en) | 2015-02-27 | 2021-03-31 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
EP3069734A1 (en) * | 2015-03-17 | 2016-09-21 | Exiris S.r.l. | Cryptophycin-based antibody-drug conjugates with novel self-immolative linkers |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
TWI660741B (en) | 2015-11-03 | 2019-06-01 | 財團法人工業技術研究院 | Antibody-drug conjugate (adc) and method for forming the same |
TWI714661B (en) * | 2015-11-05 | 2021-01-01 | 法商賽諾菲公司 | Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use |
WO2017136769A1 (en) * | 2016-02-04 | 2017-08-10 | Eisai R&D Management Co., Ltd. | Peptide drug conjugates |
WO2018178277A1 (en) | 2017-03-29 | 2018-10-04 | Avicenna Oncology Gmbh | New targeted cytotoxic isocombretaquinoline derivatives and conjugates thereof |
MA50764A (en) | 2017-05-10 | 2020-03-18 | Sanofi Sa | PEPTIDIC LINKERS AND CONJUGATES OF CRYPTOPHYCIN, USEFUL IN THERAPY, AND THEIR PREPARATION |
EP3665161B1 (en) | 2017-08-09 | 2023-09-27 | Helmholtz-Zentrum für Infektionsforschung GmbH | New targeted cytotoxic ratjadone derivatives and conjugates thereof |
CA3085600A1 (en) * | 2017-12-22 | 2019-06-27 | Cornell University | 18f-labeled peptide ligands useful in pet and cerenkov luminescene imaging |
CA3108289A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
SG11202100934PA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
FR3085952B1 (en) | 2018-09-17 | 2020-10-30 | Centre Nat Rech Scient | ANTIBODY-MEDICINAL CONJUGATE CONTAINING QUINOLINE DERIVATIVES |
JP2022549971A (en) | 2019-09-30 | 2022-11-29 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | Biocatalytic synthesis of cryptophycin anticancer agents |
EP4046996A1 (en) | 2021-02-19 | 2022-08-24 | Universität Bielefeld | Cryptophycin compounds and conjugates thereof |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
WO2023057564A1 (en) | 2021-10-07 | 2023-04-13 | Sanofi | IMIDAZO[4,5-c]QUINOLINE-4-AMINE COMPOUNDS AND CONJUGATES THEREOF, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATIONS |
US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2719170A (en) | 1954-07-28 | 1955-09-27 | Du Pont | Alkyl omega-carboxyalkyl disulfides and their lower alkyl esters |
US4981979A (en) | 1987-09-10 | 1991-01-01 | Neorx Corporation | Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity |
EP0454726A4 (en) | 1988-12-22 | 1991-11-27 | Xoma Corporation | Hindered linking agents and methods |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2056039A1 (en) | 1991-01-22 | 1992-07-23 | Philip L. Fuchs | Carbacyclin analogs |
JP4181632B2 (en) | 1995-03-07 | 2008-11-19 | ユニバーシティ オブ ハワイ | New synthetic cryptophycins |
CZ64599A3 (en) * | 1996-08-30 | 1999-10-13 | Eli Lilly And Company | Pharmaceutical compounds |
CA2347246A1 (en) | 1998-10-16 | 2000-04-27 | James Abraham Aikins | Stereoselective process for producing cryptophycins |
WO2000034252A2 (en) | 1998-12-07 | 2000-06-15 | Eli Lilly And Company | Process for the preparation of cryptophycin derivatives |
EP1482972A4 (en) * | 2001-11-20 | 2005-11-23 | Seattle Genetics Inc | Treatment of immunological disorders using anti-cd30 antibodies |
US20040249130A1 (en) * | 2002-06-18 | 2004-12-09 | Martin Stanton | Aptamer-toxin molecules and methods for using same |
DE60336149D1 (en) | 2002-08-16 | 2011-04-07 | Immunogen Inc | Highly reactive and soluble crosslinkers and their use in the preparation of conjugates for the targeted delivery of small-molecule drugs |
US7230101B1 (en) | 2002-08-28 | 2007-06-12 | Gpc Biotech, Inc. | Synthesis of methotrexate-containing heterodimeric molecules |
HUE026914T2 (en) | 2002-11-07 | 2016-08-29 | Immunogen Inc | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
CN1956722A (en) | 2003-05-20 | 2007-05-02 | 伊缪诺金公司 | Improved cytotoxic agents comprising new maytansinoids |
CN103145844B (en) | 2003-07-21 | 2016-08-03 | 伊缪诺金公司 | CA6 antigen-specific cytotoxic conjugate and application process thereof |
US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
WO2005082023A2 (en) | 2004-02-23 | 2005-09-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
GT200500283A (en) | 2004-10-08 | 2006-05-08 | IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS | |
EP1669358A1 (en) | 2004-12-07 | 2006-06-14 | Aventis Pharma S.A. | Cytotoxic agents comprising new taxanes |
PT1819359E (en) * | 2004-12-09 | 2015-05-28 | Janssen Biotech Inc | Anti-integrin immunoconjugates, methods of their production and their use |
MX2007007590A (en) | 2004-12-22 | 2007-12-10 | Ambrx Inc | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides. |
CA2600418A1 (en) | 2005-03-07 | 2006-09-14 | Archemix Corp. | Stabilized aptamers to psma and their use as prostate cancer therapeutics |
US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
EP1813614B1 (en) | 2006-01-25 | 2011-10-05 | Sanofi | Cytotoxic agents comprising new tomaymycin derivatives |
EP1832577A1 (en) | 2006-03-07 | 2007-09-12 | Sanofi-Aventis | Improved prodrugs of CC-1065 analogs |
EP2010475A2 (en) | 2006-04-27 | 2009-01-07 | Intezyne Technologies Incorporated | Heterofunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof |
EP1864682A1 (en) | 2006-06-09 | 2007-12-12 | Sanofi-Aventis | Leptomycin derivatives |
USRE47123E1 (en) | 2006-07-18 | 2018-11-13 | Sanofi | EPHA2 receptor antagonist antibodies |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
EP3569251A1 (en) * | 2007-06-25 | 2019-11-20 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
PL2019104T3 (en) | 2007-07-19 | 2014-03-31 | Sanofi Sa | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use |
US8865875B2 (en) | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
EP2276509B1 (en) | 2008-04-11 | 2016-06-15 | Seattle Genetics, Inc. | Detection and tratment of pancreatic, ovarian and other cancers |
BRPI0911442A2 (en) | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | potent conjugates and hydrophilic binders |
KR20210100223A (en) | 2008-04-30 | 2021-08-13 | 이뮤노젠 아이엔씨 | Cross-linkers and their uses |
WO2010014812A2 (en) | 2008-07-30 | 2010-02-04 | The Research Foundation Of State University Of New York | Peptide compositions and methods of use |
-
2009
- 2009-06-29 FR FR0903170A patent/FR2947269B1/en not_active Expired - Fee Related
- 2009-11-25 FR FR0905651A patent/FR2947271B1/en not_active Expired - Fee Related
-
2010
- 2010-05-20 CN CN201080038575.2A patent/CN102482238B/en not_active Expired - Fee Related
- 2010-05-20 MX MX2011013764A patent/MX2011013764A/en active IP Right Grant
- 2010-05-20 MY MYPI2011006289A patent/MY156684A/en unknown
- 2010-05-20 KR KR1020117031276A patent/KR101770584B1/en active IP Right Grant
- 2010-05-20 PE PE2011002178A patent/PE20121031A1/en not_active Application Discontinuation
- 2010-05-20 JP JP2012518108A patent/JP5746692B2/en not_active Expired - Fee Related
- 2010-05-20 EA EA201270096A patent/EA024627B1/en not_active IP Right Cessation
- 2010-05-20 CA CA2766762A patent/CA2766762C/en not_active Expired - Fee Related
- 2010-05-20 NZ NZ597136A patent/NZ597136A/en not_active IP Right Cessation
- 2010-05-20 EP EP10728799A patent/EP2448929A1/en not_active Withdrawn
- 2010-05-20 WO PCT/FR2010/050986 patent/WO2011001052A1/en active Application Filing
- 2010-05-20 BR BRPI1015131-1A patent/BRPI1015131A2/en not_active Application Discontinuation
- 2010-05-20 SG SG2011097193A patent/SG177419A1/en unknown
- 2010-05-20 MA MA34580A patent/MA33465B1/en unknown
- 2010-05-20 SG SG10201607595WA patent/SG10201607595WA/en unknown
- 2010-06-28 TW TW099121094A patent/TW201110986A/en unknown
- 2010-06-28 AR ARP100102290A patent/AR078131A1/en unknown
- 2010-06-29 UY UY0001032745A patent/UY32745A/en not_active Application Discontinuation
-
2011
- 2011-12-05 DO DO2011000376A patent/DOP2011000376A/en unknown
- 2011-12-12 TN TNP2011000636A patent/TN2011000636A1/en unknown
- 2011-12-13 CR CR20110670A patent/CR20110670A/en unknown
- 2011-12-15 SV SV2011004086A patent/SV2011004086A/en unknown
- 2011-12-19 NI NI201100219A patent/NI201100219A/en unknown
- 2011-12-20 CL CL2011003229A patent/CL2011003229A1/en unknown
- 2011-12-20 US US13/331,259 patent/US8952147B2/en not_active Expired - Fee Related
- 2011-12-23 ZA ZA2011/09537A patent/ZA201109537B/en unknown
- 2011-12-26 IL IL217208A patent/IL217208A/en not_active IP Right Cessation
- 2011-12-26 EC EC2011011553A patent/ECSP11011553A/en unknown
- 2011-12-28 HN HN2011003414A patent/HN2011003414A/en unknown
- 2011-12-29 CO CO11180696A patent/CO6430462A2/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL217208A0 (en) | Novel conjugates, preparation thereof, and therapeutic use thereof | |
HRP20181493T1 (en) | Epsilon-polylysine conjugates and use thereof | |
IL222930A0 (en) | Chlorotoxin variants, conjugates and methods for their use | |
HK1159108A1 (en) | Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof | |
ZA201300685B (en) | Anticancer derivatives,preparation thereof and therapeutic use thereof | |
IL218490A0 (en) | Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof | |
HK1151791A1 (en) | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | |
IL215684A0 (en) | Trehalulose-containing composition, its preparation and use | |
IL219888A0 (en) | Pyridine-pyridinone derivatives, preparation and therapeutic use thereof | |
ZA201107363B (en) | Quinazolinedione derivatives,preparation thereof and various therapeutic uses thereof | |
IL207629A0 (en) | Novel 3-aminoalkyl-1,3-dihydro-2h-indol-2-one derivatives, preparation thereof and therapeutic use thereof | |
IL216203A0 (en) | Lipid-polymer conjugates, their preparation and uses thereof | |
HRP20180744T1 (en) | Therapeutic vaccines | |
HK1164861A1 (en) | Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation thereof, and therapeutic use thereof | |
IL202474A0 (en) | 1-benzylpyrazole derivatives, preparation thereof and therapeutic use thereof | |
EP2408808A4 (en) | Terminally-functionalized conjugates and uses thereof | |
SI2421864T1 (en) | 1-pyrazološ4,3-cćisoquinoline derivatives, preparation thereof and therapeutic use thereof | |
GB201010500D0 (en) | Therapeutic conjugates | |
IL226388A0 (en) | Novel indolizine derivatives, and preparation and therapeutic use thereof | |
AU2010267917B9 (en) | Novel conjugates, preparation thereof, and therapeutic use thereof | |
ZA201205056B (en) | Therapeutic use of protein-polymer conjugates | |
IL220859A0 (en) | Alkyl-heterocycle-carbamate derivatives, their preparation and therapeutic application | |
GB0922098D0 (en) | Therapeutic use | |
IL218330A0 (en) | Oligo-and polyfurans, preparation and uses thereof | |
GB0801424D0 (en) | Therapeutic vaccines |